Amoxapine shows atypical antipsychotic effects in patients with schizophrenia: Results from a prospective open-label study

Schizophrenia Research

Volumn 59, Issue 1, 2003, Pages 35-39

  Apiquian, Rogelio ^a,b   Ulloa, Elena ^a,c   Fresan, Ana ^a,b   Loyzaga, Cristina ^a,b   Nicolini, Humberto ^a,b   Kapur, Shitij ^d,e  

^a Grupo Medico Carracci   (Mexico)

^b INSTITUTO NACIONAL DE PSIQUIATRÍA RAMÓN DE LA FUENTE MUÑIZ   (Mexico)

^c Hospital Psiquiatrico Infantil Dr Juan N Navarro   (Mexico)

^d UNIVERSITY OF TORONTO   (Canada)

^e CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Antidepressant; Antipsychotic; Atypical; Dopamine; Schizophrenia; Serotonin

Indexed keywords

AMOXAPINE; ATYPICAL ANTIPSYCHOTIC AGENT;

ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERANCE; EMOTIONAL DISORDER; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MOOD DISORDER; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; TITRIMETRY; TREATMENT OUTCOME; WEIGHT GAIN;

ADOLESCENT; ADULT; AMOXAPINE; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROTRANSMITTER UPTAKE INHIBITORS; PROSPECTIVE STUDIES; SCHIZOPHRENIA;

EID: 0037210066     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(01)00342-5     Document Type: Article

References (22)

1. Addington D., Addington J., Maticka-Tyndale E., Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr. Res. 6:1992;201-208.
2. Anton R.F. Jr., Burch E.A. Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am. J. Psychiatry. 147:1990;1203-1208.
3. Anton R.F., Sexauer J.D., Randall C.L. Amoxapine elevates serum prolactin in depressed men. J. Affective Disord. 5:1983;305-310.
4. Apiquian R., Páez F., Loyzaga C., Cruz E., Gutiérrez D., Suárez J. Mexican study on the first psychotic episode: preliminary results, sociodemographic and clinical characteristics. Salud Mental. 20:1997;1-17.
5. Arnt J., Skarsfeldt T., Hyttel J. Differentiation of classical and novel antipsychotics using animal models. Int. Clin. Psychopharmacol. 12(Suppl. 1):1997;S9-S17.
6. Barnes T.R.E. A rating scale for drug-induced akathisia. Br. J. Psychiatry. 154:1989;672-676.
7. D'Mello D.A., Nasrallah H.A. Suppression of tardive dyskinesia with amoxapine: case report. J. Clin. Psychiatry. 47:1986;148.
8. Greenblatt E.N., Lippa A.S., Osterberg A.C. The neuropharmacological actions of amoxapine. Arch. Int. Pharmacodyn. Ther. 233:1978;107-135.
9. Guy, W., 1976. ECDEU Assessment Manual for Psychopharmacology, DHEW publication No. (ADM)76-388. Rockville, MD, USA: US Department of Health, Education and Welfare, National Institute of Mental Health.
10. Kapur S., Cho R., Jones C., McKay G., Zipursky R.B. Is amoxapine an atypical antipsychotic? Positron-emission tomography investigation of its dopamine2 and serotonin2 occupancy. Biol. Psychiatry. 45:1999;1217-1220.
11. Kapur S., Zipursky R.B., Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry. 156:1999;286-293.
12. Kay S.R., Fiszbein A., Vital-Herne M., Fuentes L.S. The positive and negative syndrome scale - Spanish adaptation. J. Nerv. Ment. Dis. 178:1990;510-517.
13. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side-effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side-effects in neuroleptic-treated patients. Acta Psychiatr. Scand., Suppl. 334:1987;1-100.
14. Lydiard R.B., Gelenberg A.J. Amoxapine - an antidepressant with some neuroleptic properties? A review of its chemistry, animal pharmacology and toxicology, human pharmacology, and clinical efficacy. Pharmacotherapy. 1:1981;163-178.
15. Ortega H., Gracia S., Imaz B., Pacheco J., Brunner E., Apiquian R., de la Torre M. Validity and reproducibility of a scale for the evaluation of depression in schizophrenic patients. Salud Mental. 17:1994;7-14.
16. Seeman P., Kapur S. Olanzapine binding to dopamine receptors in vitro and in vivo. Tran P., Bymaster F., Tye N., Herrera J., Brier A., Tollefson G.D. Olanzapine - A Novel Antipsychotic. 2000;3-25 Lippincott Williams and Wilkins, Baltimore.
17. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side-effects. Acta Psychiatr. Scand., Suppl. 212:1970;11-19.
18. Stanniland C., Taylor D. Tolerability of atypical antipsychotics. Drug Saf. 22:2000;195-214.
19. Tao G.K., Harada D.T., Kootsikas M.E., Gordon M.N., Brinkman J.H. Amoxapine-induced tardive dyskinesia. Drug Intell. Clin. Pharm. 19:1985;548-549.
20. Turrone P., Kapur S., Seeman M., Flint A.J. Elevation of prolactin by atypical antipsychotics. Am. J. Psychiatry. 59:2002;133-150.
21. Wadenberg M.L., Hicks P.B. The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci. Biobehav. Rev. 23:1999;851-862.
22. Wadenberg M.G., Sills T.L., Fletcher P.J., Kapur S. Antipsychotic-like effects of amoxapine, without catalepsy, using the prepulse inhibition of the acoustic startle reflex test in rats. Biol. Psychiatry. 47:2000;670-676.